(NASDAQ:IMMX) IMMIX BIOPHARM INC. share are rallying this morning in pre-market up to $2.66 a share.  Shares are up more than 43% on more than 21,000 trades one hour before the open.

ImmixBio IMX-110 Demonstrated Improved Survival Over U.S. Food and Drug Administration Approved Drug Trabectedin (sold as YONDELIS by Janssen, a Johnson & Johnson Company) in Connective Tissue Cancer Soft Tissue Sarcoma Mice Study

  • One cycle of IMX-110 produced 75% survival vs. 0% survival for Trabectedin (sold as YONDELIS by Janssen, a Johnson & Johnson Company, a U.S. FDA approved drug)
  • In a connective tissue cancer Soft Tissue Sarcoma (STS) mice study, IMX-110 was compared against approved drugs
  • IMX-110 is in clinical development for STS, a $3 billion market expected to grow to $6.5 billion by 2030

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/38fdaa24-38ff-482c-8b72-63baa730a3a2

https://www.globenewswire.com/news-release/2022/05/20/2447697/0/en/ImmixBio-IMX-110-Demonstrated-Improved-Survival-Over-U-S-Food-and-Drug-Administration-Approved-Drug-Trabectedin-sold-as-YONDELIS-by-Janssen-a-Johnson-Johnson-Company-in-Connective-.html

Signup today for free and be the first to get notified of breaking news.

SIGN UP FOR OUR NEWSLETTER

Sign up for Breaking Alerts, our newsletter putting timely and updated stock and crypto markets news into your hands.

Add New Playlist